Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Coagulation Factor Deficiency Market Today And What Is Its Future Size?

The market size for coagulation factor deficiency has notably expanded in the past few years. The market is projected to balloon from $4.58 billion in 2024 to $4.93 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.7%. This historical growth is accounted for by factors including a surge in hemophilia cases, the unveiling of recombinant factors, enhanced public understanding of coagulation disorders, improved diagnostic methods, government backing for uncommon diseases, the advent of prophylactic treatments, the enlargement of patient registries, and a hike in biotech investments.

The market for coagulation factor deficiency is poised for robust growth in the upcoming years, anticipated to balloon to $6.58 billion by 2029 with a CAGR of 7.5%. Factors such as a rising acceptance of gene therapies, the escalating focus on personalized treatments, increasing occurrence of coagulation disorders, wider access in rising markets, incorporation of digital health solutions, and unending innovation in biomanufacturing technologies are expected to contribute to this growth during the forecast period. Notable trends for this time include advancements in gene editing technologies like CRISPR, the creation of long-acting recombinant factors, progress in gene therapy delivery systems, adoption of wearable coagulation monitoring devices, use of artificial intelligence for treatment enhancements, development of point-of-care diagnostic tools, nanoparticle-aided drug delivery, development of plasma-free recombinant products, biosimilar innovation, and the integration of precision medicine strategies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp

Which Key Factors Are Fueling Growth In The Coagulation Factor Deficiency Market?

The coagulation factor deficiency market is projected to grow due to the rising occurrences of blood-based disorders. These disorders, which impact the creation, function, or composition of blood cells, platelets or plasma, can cause diseases such as anemia, clotting issues, and immune system deficiencies. The surge in such disorders is due to an aging population, genetic risks, increasing awareness, environmental aspects, lifestyle modifications, chronic illnesses and improved diagnostic technologies enabling early detection. Coagulation factor deficiency aids in controlling blood-based diseases by delivering crucial clotting factors to curtail excessive bleeding, notably in illnesses like hemophilia. For instance, Leukemia and Lymphoma Society reported in September 2024 that every three minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. Around 187,740 people were diagnosed with these cancers in 2024, marking 9.4% out of the estimated 2,001,140 new cancer cases in the US. Additionally, as per the NHS England in May 2024, about 17,000 people in England live with the inherited blood disorder, sickle cell disease, with approximately 250 new cases identified each year. Hence, the burgeoning incidence of blood-related disorders is fueling the expansion of the coagulation factor deficiency market.

How Is The Coagulation Factor Deficiency Market Segmented Across Key Categories?

The coagulation factor deficiencymarket covered in this report is segmented –

1) By Product: Recombinant Coagulation Factor Concentrates; Plasma-derived Coagulation Factor Concentrates; Biologics; Desmopressin; Other Product Types

2) By Deficiency Type: Haemophilia A; Hemophilia B; Von Willebrand Disease; Factor XI Deficiency; Factor XIII Deficiency; Other Treatment Types

3) By End Users: Hospitals; Clinics; Home Care; Other End Users

Subsegments:

1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII; Recombinant Factor IX; Recombinant Factor VIIa; Other Recombinant Factors

2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII; Plasma-derived Factor IX; Plasma-derived Factor VII; Other Plasma-derived Factors

3) By Biologics: Monoclonal Antibodies; Gene Therapy Products

4) By Desmopressin: Intravenous Desmopressin; Intranasal Desmopressin

5) By Other Product Types: Fresh Frozen Plasma (FFP); Prothrombin Complex Concentrates (PCC)

What Key Trends Are Driving Growth In The Coagulation Factor Deficiency Market?

Leading firms in the coagulation factor deficiency market are centering their efforts on creating groundbreaking therapies like one-time gene therapy, aiming to offer sustained or potentially healing remedies for individuals suffering from bleeding ailments like hemophilia. This would minimize the necessity for regular infusions of clotting factors throughout their lifetime. One-time gene therapy, as the term suggests, is a healthcare procedure that modifies or inputs genetic content within a patient’s cells to treat or possibly cure a disease, offering ongoing or permanent therapeutic advantages after a one-time administration. To illustrate, in April 2024, Pfizer Inc., a pharmaceutical and biotech firm based in the United States, stated that the U.S. Food and Drug Administration (FDA) has endorsed BEQVEZ (fidanacogene elaparvovec-dzkt) for the management of adults with moderate to severe hemophilia B who are presently undergoing factor IX (FIX) prophylactic treatment. This one-time gene therapy, which uses an adeno-associated virus (AAV), is engineered to deliver a functional copy of the FIX gene, which codes a high-activity FIX variant, to the transduced cells. As a result, patients with hemophilia B can produce FIX on their own following this single treatment, eliminating the need for frequent FIX infusions.

Who Are The Leading Companies Driving The Coagulation Factor Deficiency Market?

Major companies operating in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report

Which Region Dominates The Coagulation Factor Deficiency Market Today?

North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21152&type=smp

Browse Through More Reports Similar to the Global Coagulation Factor Deficiency Market 2025, By The Business Research Company

Coagulation Analyzer Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/coagulation-analyzer-global-market-report

Point Of Care Poc Coagulation Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-global-market-report

5 Alpha Reductase Deficiency Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model